Global Lyophilized Injectable Drugs Market, By Packaging (Vials, Dual-Chamber Syringes, Dual-Chamber Cartridges, Specialty Packaging, Point-Of-Care Reconstitution, Single-Use Vials, and Others),Type of Delivery (Single-Step Devices, Multi-Step Devices, Prefilled Diluent Syringes, and Proprietary Reconstitution Devices), Drug Class (Anti-Infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, Corticosteroids and Others), Form (Powder and Liquid), Indication (Oncology, Autoimmune Diseases, Hormonal Disorders, Metabolic Conditions, Respiratory Diseases, Gastrointestinal Disorders, Dermatological Disorders, Ophthalmic Diseases, Infectious Diseases, and Others), Route of Administration (Intravenous/Infusion, Intramuscular and Others), End User (Hospital, Clinics, Ambulatory Surgery Centers (ASCs), Home Healthcare and Others), Distribution Channel (Direct Tender, Retail Sales and Others) – Industry Trends and Forecast to 2031.
Lyophilized Injectable Drugs Market Analysis and Size
Lyophilized injectable drugs are vital in treating diverse medical conditions such as infections, cancer, and autoimmune diseases. They provide convenient and effective treatment options globally, especially for patients with chronic ailments, ensuring reliable access to essential medications for managing their health effectively.
Data Bridge Market Research analyses that the global lyophilized injectable drugs market, which was USD 3,196.39 million in 2023, is expected to reach USD 5,171.96 million by 2031, and is expected to undergo a CAGR of 6.2% during the forecast period of 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lyophilized Injectable Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Packaging (Vials, Dual-Chamber Syringes, Dual-Chamber Cartridges, Specialty Packaging, Point-Of-Care Reconstitution, Single-Use Vials, and Others),Type of Delivery (Single-Step Devices, Multi-Step Devices, Prefilled Diluent Syringes, and Proprietary Reconstitution Devices), Drug Class (Anti-Infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, Corticosteroids and Others), Form (Powder and Liquid), Indication (Oncology, Autoimmune Diseases, Hormonal Disorders, Metabolic Conditions, Respiratory Diseases, Gastrointestinal Disorders, Dermatological Disorders, Ophthalmic Diseases, Infectious Diseases, and Others), Route of Administration (Intravenous/Infusion, Intramuscular and Others), End User (Hospital, Clinics, Ambulatory Surgery Centers (ASCs), Home Healthcare and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Affy Pharma Pvt Ltd. (India), GENEX PHARMA (India), Aurobindo Pharma USA (U.S.), Astellas Pharma Inc. (U.S.), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Cirondrugs (India), Amneal Pharmaceuticals LLC (U.S.), Jubilant Generics Limited (India), Novartis AG (Switzerland), Otsuka America Pharmaceutical, Inc. (U.S.), Zydus Group (India), Cipla Inc. (India), Merck & Co., Inc. (Germany), Fresenius Kabi AG (U.S.), Sanofi (France), CELON LABS (India) and Baxter (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Lyophilized injectable drugs are pharmaceutical products that undergo freeze-drying to remove water from their formulations, resulting in a stable, solid state. This process enables long-term storage and enhances drug stability, particularly important for sensitive biologics and vaccines, which can be reconstituted with a solvent before administration.
Global Lyophilized Injectable Drugs Market Dynamics
Drivers
- Global Pandemic Preparedness by Vaccine Preservation
The COVID-19 pandemic has heightened attention on lyophilized drugs for their role in vaccine development and storage. Their stability and extended shelf life make them vital tools for ensuring global health preparedness, offering solutions for vaccine preservation and distribution during crises, underscoring their importance in pandemic response strategies and vaccine supply chain management.
- Increasing Geriatric Population with Chronic Illness
The growing elderly demographic, susceptible to chronic illnesses, drives demand for lyophilized injectable drugs, prized for their reliability and effectiveness in treatment. As this population segment expands, there is a heightened need for pharmaceutical solutions that offer enhanced stability and convenience, aligning with the requirements of aging patients and healthcare providers.
Opportunities
- Expanding Healthcare Infrastructure Enhance Accessibility
Investments in healthcare infrastructure in developing regions create opportunities for expanding the market for lyophilized drugs. Improved healthcare facilities and distribution networks enhance accessibility to these medications, addressing unmet medical needs and driving market growth. This trend reflects a growing commitment to healthcare advancement and improved patient care in emerging economies.
- Personalized Medicine for Better Therapeutic Outcomes
Advancements in precision medicine and targeted therapies are fueling the demand for customized lyophilized formulations in personalized medicine. Tailored to individual patient needs and treatment efficacy, these formulations offer precise dosing and delivery, optimizing therapeutic outcomes. This trend reflects the growing importance of personalized approaches in modern healthcare.
Restraints/Challenges
- Packaging Issues Impacting Product Quality
Preserving product integrity in lyophilized injectable drugs involves designing containers that withstand freeze-drying and maintain stability post-lyophilization. Achieving compatibility between packaging materials and drugs is complex, impacting quality, safety, and regulatory compliance. Packaging challenges pose a significant hurdle in the market.
- High Production Costs Limit Affordability
High production costs associated with lyophilization hinder market accessibility by inflating drug pricing. These elevated expenses, stemming from specialized equipment and expertise needed for the process, limit affordability for patients and healthcare systems. Consequently, accessibility to lyophilized drugs becomes restricted, hindering their widespread adoption and potentially impeding market growth.
This global lyophilized injectable drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lyophilized injectable drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In November 2022, Telstar expanded its process laboratory service for freeze-drying and sterilization, incorporating cold sterilization methods for non-compatible medical and pharmaceutical products alongside conventional high-temperature sterilization, enhancing its offerings and capabilities in the industry
- In March 2021, Zydus Cadila reduced the cost of its drug Remdac, a generic version of Remdesivir used for COVID-19 patients in India. This strategic move bolstered demand and sales, elevating the company's credibility in the market
- In August 2020, Jubilant Pharma Limited launched JUBI-R, Remdesivir for injection, amidst the COVID-19 pandemic. This timely introduction enhanced the company's reputation and market demand, displaying its responsiveness to critical healthcare needs
- In July 2020, Fondaco Pte Ltd recalled its product euronox Lyophilized Powder for Injection 100 units/vial due to potential quality issues, impacting its credibility and market demand negatively, underscoring the importance of product quality control and assurance measures
Global Lyophilized Injectable Drugs Market Scope
The global lyophilized injectable drugs market is segmented on the basis of packaging, type of delivery, drug class, form, indication, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Packaging
- Vials
- Dual-Chamber Syringes
- Dual-Chamber Cartridges
- Specialty Packaging
- Point-Of-Care Reconstitution
- Single-Use Vials
- Others
Type of Delivery
- Single-Step Devices
- Multi-Step Devices
- Prefilled Diluent Syringes
- Proprietary Reconstitution Devices
Drug Class
- Anti-Infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Corticosteroids
- Others
Form
- Powder
- Liquid
Indication
- Oncology
- Autoimmune Diseases
- Hormonal Disorders
- Metabolic Conditions
- Respiratory Diseases
- Gastrointestinal Disorders
- Dermatological Disorders
- Ophthalmic Diseases
- Infectious Diseases
- Others
Route of Administration
- Intravenous/Infusion
- Intramuscular
- Others
End User
- Hospital
- Clinics
- Ambulatory Surgery Centers (ASCs)
- Home Healthcare
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Global Lyophilized Injectable Drugs Market Regional Analysis/Insights
The global lyophilized injectable drugs market is analysed and market size insights and trends are provided by country, packaging, type of delivery, drug class, form, indication, route of administration, end user and distribution channel as referenced above.
The countries covered in the global lyophilized injectable drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to witness high growth in the lyophilized injectable drugs market, particularly in the U.S. The vials segment is projected to dominate, benefiting from lower prices compared to other packing materials, supported by major market players and technological advancements in the region.
Asia-Pacific is expected to dominate the lyophilized injectable drugs market due to rising demand for these medications to treat various diseases. Japan, in particular, is emerging as a key player in the region, driven by increasing demand for lyophilized drugs across therapeutic areas.
Europe is expected to dominate in the lyophilized injectable drugs market, with the vials segment leading in Germany. The region's dominance is attributed to the rising number of research and development laboratories for drug testing, particularly in Germany, fostering demand for lyophilized injectable drugs packaged in vials.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global lyophilized injectable drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global lyophilized injectable drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global lyophilized injectable drugs market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Lyophilized Injectable Drugs Market Share Analysis
The global lyophilized injectable drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lyophilized injectable drugs market.
Some of the major players operating in the global lyophilized injectable drugs market are:
- Affy Pharma Pvt Ltd. (India)
- GENEX PHARMA (India)
- Aurobindo Pharma USA (U.S.)
- Astellas Pharma Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Viatris Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Cirondrugs (India)
- Amneal Pharmaceuticals LLC (U.S.)
- Jubilant Generics Limited (India)
- Novartis AG (Switzerland)
- Otsuka America Pharmaceutical, Inc. (U.S.)
- Zydus Group (India)
- Cipla Inc. (India)
- Merck & Co., Inc. (Germany)
- Fresenius Kabi AG (U.S.)
- Sanofi (France)
- CELON LABS (India)
- Baxter (U.S.)
SKU-